Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

Advanced search

PHARMACOECONOMIC ANALYSIS OF VESOMNI (SOLIFENACIN AND CONTROLLED RELEASE TAMSULOSIN) TREATMENT OF STORAGE SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA

https://doi.org/10.17749/2070-4909.2016.9.2.003-010

Full Text:

Abstract

The aim of the current study is pharmacoeconomic evaluation of using combined drug Vesomni (controlled release tablets tamsulosin 0.4 mg + solifenacin 6 mg) for treatment of patients with storage symptoms associated with benign prostatic hyperplasia, who do not respond to first line tamsulosin therapy.

Materials and methods. We consider three therapy options: 1) combined drug Vesomni; 2) combination of tamsulosin (modified release capsules 0.4 mg) and solifenacin (5 mg); 3) combination of tamsulosin (controlled release tablets 0.4 mg) and solifenacin (5 mg). These options are evaluated with cost minimization and budget impact analysis.

Results. We found that approx. 250,000 patients in Russia need combined tamsulosin and solifenacin therapy, including 35,400 patients eligible for government reimbursement. Using combined drug is cost saving alternative that annually requires 22,000 rubles per patient, which is 2,000 rubles less than second best option. The overall healthcare annual expenses of using combined drug are 5,7 billion rubles (500 million rubles less than for second best option), and government reimbursement costs are 606 million rubles (74 million less than for second best option).

Conclusion. Using combined drug Vesomni for treatment of patients with storage symptoms associated with benign prostatic hyperplasia is cost saving alternative compared to combination of monotheraphy regimens.

About the Authors

N. A. Avxentyev
Research Institute of Finance, Ministry of Finance of the Russian Federation; Russian Presidential Academy of National Economy and Public Administration
Russian Federation

adviser;

research fellow of Institute of social analysis and forecasting,

Nastasyinsky per., 3-2, Moscow, 127006



M. Yu. Frolov
Volgograd State Medical University of the Ministry of Health Russian Federation; Interregional Association for Clinical Pharmacology
Russian Federation

PHD (candidate of medical sciences), assistant professor (FUV module) of Clinical pharmacology and intensive therapy department

Pavshih borzov pl., 1, Volgograd, 400131



References

1. Data NES Center for Demographic Research (in Russian). URL: http://demogr.nes.ru/index.php/ru/demogr_indicat/data (accessed: 23.02.2016)

2. Incidence of the population of Russia in 2014: statistical data: in X hours [Zabolevaemost' naseleniya Rossii v 2014 godu: statisticheskie materialy: v X ch. (in Russian)] Moscow. 2015.

3. Sevryukov F. A. Complex medical-social and clinico-economic aspects of the prevention and treatment of benign prostatic hyperplasia. Dr. diss. [Kompleksnye mediko-sotsial'nye i kliniko-ekonomicheskie aspekty profilaktiki i lecheniya dobrokachestvennoi giperplazii predstatel'noi zhelezy (in Russian)]. Moscow. 2012; 309 s.

4. Bangalore S. et al. Fixed-dose combinations improve medication compliance: a meta-analysis. The American journal of medicine. 2007; 120 (8): 713-719.

5. Bruskewitz R. Management of symptomatic BPH in the US: who is treated and how? European urology. 1999; 36 (3): 7-13.

6. Chapple C. R. et al. Tamsulosin oral controlled absorption system (OCAS) in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): efficacy and tolerability in a placebo and active comparator controlled phase 3a study. European Urology Supplements. 2005; 4 (2): 33-44.

7. Drake M. J. et al. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension. European urology. 2015; 67 (2): 262-270.

8. Hakimi Z. et al. Drug treatment patterns for the management of men with lower urinary tract symptoms associated with benign prostatic hyperplasia who have both storage and voiding symptoms: a study using The Health Improvement Network UK primary care data. Current medical research and opinion. 2015; 31 (1): 43-50.

9. Homma Y. et al. Epidemiologic survey of lower urinary tract symptoms in Asia and Australia using the international prostate symptom score. International journal of urology. 1997; 4 (1): 40-46.

10. LMMG New Medicine Recommendation. Vesomni for the treatment of Storage Symptoms associated with Benign Prostatic Hyperplasia. URL: http://www.lancsmmg.nhs.uk/wp-content/uploads/sites/3/2014/05/MR140303-VESOMNI-CSU-New-Medicine-ReviewFinal-Recommendation-following-LMMG_WEBSITE.pdf (accessed: 23.02.2016).

11. Michel M. C. et al. Cardiovascular safety of the oral controlled absorption system (OCAS) formulation of tamsulosin compared to the modified release (MR) formulation. European Urology Supplements. 2005; 4 (2): 53-60.

12. Mitropoulos D. et al. Symptomatic benign prostate hyperplasia: impact on partners’ quality of life. European urology. 2002; 41 (3): 240-245.

13. National Clinical Guideline Centre. The management of lower urinary tract symptoms in men. National Clinical Guideline Center, 2010. URL: http://www.nice.org.uk/usingguidance/commissioningguides/luts/LUTS.jsp (accessed: 23.02.2016).

14. Nazir J. et al. Cost-effectiveness of a fixed-dose combination of solifenacin and oral controlled adsorption system formulation of tamsulosin in men with lower urinary tract symptoms associated with benign prostatic hyperplasia . BMC urology. 2015; 15 (1): 1.

15. Oelke M. et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. European urology. 2013; 64 (1): 118-140.

16. Sexton C. C. et al. The overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA, UK and Sweden: EpiLUTS. BJU international. 2009; 103 (3): 12-23.

17. Toledo A. et al. Cost-Effectiveness Of A Fixed-Dose Combination Of Solifenacin Plus Tamsulosin Ocas For The Treatment Of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia In Spain. Value in Health. 2015; 18 (7): A510.


For citation:


Avxentyev N.A., Frolov M.Y. PHARMACOECONOMIC ANALYSIS OF VESOMNI (SOLIFENACIN AND CONTROLLED RELEASE TAMSULOSIN) TREATMENT OF STORAGE SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA. FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology. 2016;9(2):3-10. (In Russ.) https://doi.org/10.17749/2070-4909.2016.9.2.003-010

Views: 534


ISSN 2070-4909 (Print)
ISSN 2070-4933 (Online)